Auteur
Matthew Royle

Matthew Royle, Ph.D.

Associé

Read More
Auteur
Matthew Royle

Matthew Royle, Ph.D.

Associé

Read More

7 août 2020 | 01:00:50

Biologics and biosimilars litigation update

Tune in to the second in our 2020 webinar series on decisions in the US and Europe impacting biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, companies continue to face a great deal of uncertainty due to unresolved legal questions involving the governing statutes and patent rights.

Session 2 of this series focuses on recent key decisions, including:

  • Recent Federal Circuit decisions involving biologics and biosimilars.
  • Updates in the US “patent thicket” antitrust litigation.
  • Recent developments in Europe including Kymab v Regeneron Supreme Court judgment in the UK.
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

centrifuge-machine
Sciences de la vie et Santé

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

27 juillet 2020
QUICK READ

par plusieurs auteurs

Cliquer ici pour en savoir plus

Événements connexes